Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Arformoterol/budesonide - Korea United Pharm

Drug Profile

Arformoterol/budesonide - Korea United Pharm

Alternative Names: Budesonide/arformoterol - Korea United Pharm; UI 030

Latest Information Update: 01 Apr 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Korea United Pharm Inc
  • Class Amides; Anti-inflammatories; Antiallergics; Antiasthmatics; Antivirals; Bronchodilators; Ethanolamines; Ethers; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - COVID 2019 infections

Highest Development Phases

  • Preclinical COVID 2019 infections

Most Recent Events

  • 17 Jan 2022 Arformoterol/budesonide - Korea United Pharm is available for licensing as of 17 Jan 2022. https://www.kup.co.kr/research/innovation_main.htm (Korea United Pharm, website, January 2022)
  • 17 Jan 2022 Korea United Pharm plans to launch arformoterol/budesonide for COVID-2019 infections in 2022 (Korea United Pharm pipeline, January 2022)
  • 30 Sep 2021 Korea United Pharm plans a phase II trial for COVID-2019 infections (In adults, In elderly) (NCT05055414)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top